Journal of Parkinson's disease最新文献

{"title":"Predicting motor function improvement following deep brain stimulation of the subthalamic nucleus for Parkinson's disease based on STN-T2MRI radiomics.","authors":"Zhenke Li, Jinxing Sun, Haopeng Lin, Qianqian Wu, Junheng Jia, Xing Guo, Weiguo Li","doi":"10.1177/1877718X251319697","DOIUrl":"https://doi.org/10.1177/1877718X251319697","url":null,"abstract":"<p><p>BackgroundMagnetic resonance imaging (MRI) findings for neural nuclei are an important reference for the diagnosis of Parkinson's disease (PD) and target localization in deep brain stimulation (DBS). The MRI characteristics of the subthalamic nucleus (STN) in PD patients are heterogeneous and may be indicative of differing levels of motor dysfunction in these individuals.ObjectiveTo investigate whether the radiological characteristics of the STN on preoperative T2-MRI can assist in predicting motor function improvement in PD patients following STN-DBS through radiomics.Methods137 patients with good improvement (Good) and 72 patients with poor improvement (Poor) were enrolled. T2-MRI images of the STN were used to extract radiomics features. Three machine learning models were used to classify the patients according to their radiomics features. Finally, the performance and clinical benefits of the models (radiomics model, clinical model, and clinical-radiomics model) were evaluated by calibration curve, receiver operating characteristic (ROC) curve, and decision curve analysis (DCA).ResultsThe logistic regression and support vector machine models optimally distinguished Good and Poor, with areas under the curve (AUCs) of 0.844 and 0.853, respectively. The ROC curve, calibration curves, and DCA demonstrated that the integrated clinical-radiomics model had the highest clinical benefit among all models tested, in the test set (accuracy 0.876 and AUC 0.937).ConclusionsThe combined model incorporating the radiomics features of the STN and clinical features predicted motor function improvement following STN-DBS for PD well and may provide a noninvasive and effective approach for evaluating surgical indications.</p>","PeriodicalId":16660,"journal":{"name":"Journal of Parkinson's disease","volume":" ","pages":"1877718X251319697"},"PeriodicalIF":4.0,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143670207","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Investigating the prevalence of the G2019S mutation in Parkinson's disease among a Libyan population.","authors":"Nuri H Awayn, Sara A Hashish, Sultan A Salem, Sulieman Abod, Sana M Elgahmasi, Khalid Ouararhni, Houari Abdesselem, Ilham Y Abdi, Omar A El-Agnaf","doi":"10.1177/1877718X251324407","DOIUrl":"https://doi.org/10.1177/1877718X251324407","url":null,"abstract":"<p><p>Parkinson's disease (PD) is a progressive neurodegenerative disorder influenced by both environmental and genetic risk factors. This study investigates the prevalence of the <i>LRRK2</i> G2019S mutation in a Libyan population of 140 PD patients and 58 controls. Genetic analysis of blood samples revealed that 19.5% of PD patients carry the G2019S mutation, indicating a genetic association with the disease. The study highlights the G2019S mutation as a potential genetic risk factor for PD in Libya and emphasizes the importance of genetic screening for better understanding and management of the disease.</p>","PeriodicalId":16660,"journal":{"name":"Journal of Parkinson's disease","volume":" ","pages":"1877718X251324407"},"PeriodicalIF":4.0,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143676631","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Integrating virtual reality into multidisciplinary care for Parkinson's disease: A narrative review.","authors":"Daniela Pimenta Silva, Filipa Pona-Ferreira, Ricardo Cacho, Beatriz Santos, Teresa Lobo, Raquel Bouça-Machado, Joaquim J Ferreira","doi":"10.1177/1877718X251323916","DOIUrl":"https://doi.org/10.1177/1877718X251323916","url":null,"abstract":"<p><p>Parkinson's disease (PD) is a neurodegenerative disorder characterized by both motor and non-motor symptoms, significantly impacting patients' functionality and quality of life. Clinical exercise, as part of a multidisciplinary approach, is gaining a crucial role in PD management. Goal-based exercises, combining physical activity with cognitive tasks, external feedback and cues, motor sequencing strategies and dual-tasking may enhance motor learning processes and guide physiotherapy programs.Virtual reality (VR) and exergaming have also emerged as promising tools in PD rehabilitation, offering challenging activities in multisensory environments. They provide intensive and repetitive training, augmented feedback, and tailored exercises in highly interactive and enriched environments. Clinical studies have presented promising results in people with PD, supported by neuroimaging studies showing distinct brain activation patterns post-VR training. However, heterogeneity in study design and lack of standardized characterization of VR systems hinder further application in PD rehabilitation.In this review, we appraise the distinguishing features between different VR systems, highlight VR-related motor and cognitive training in PD and explore how VR interventions are aligned with principles of neuroplasticity and motor learning in PD.</p>","PeriodicalId":16660,"journal":{"name":"Journal of Parkinson's disease","volume":" ","pages":"1877718X251323916"},"PeriodicalIF":4.0,"publicationDate":"2025-03-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143649445","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recognition, management, and patient perspectives of impulsive-compulsive disorders in Parkinson's disease.","authors":"Mirjam Wolfschlag, Gustav Cedergren Weber, Jonathan Timpka, Daniel Weintraub, Per Odin, Anders Håkansson","doi":"10.1177/1877718X251323922","DOIUrl":"https://doi.org/10.1177/1877718X251323922","url":null,"abstract":"<p><p>BackgroundImpulsive-compulsive disorders (ICDs) are commonly acknowledged as side effects of dopaminergic therapy in Parkinson's disease (PD). While many large-scale studies have focused on prevalences and high-risk treatments, little is known about practical management of ICDs in clinical care and patients' experiences.ObjectiveTo investigate how ICDs are recognized in clinical PD care, clinical features of patients with ICDs, and how patients are impacted by their ICD.MethodsQuestionnaires were sent to all patients who reported ICD symptoms in the Swedish quality register for PD in Skåne County (n = 170) and patients' medical records were screened for mention of ICDs. Core subjects were communication between clinician and patient, course and management of ICDs, and impact on different life domains.ResultsDespite sufficient awareness of the ICD risk during PD treatment, there was limited communication between clinical care staff and patients regarding ICDs. Only 49% of patients had reported their ICD as part of clinical care, and only 14% had been asked about it. Additionally, collaboration with psychiatry was rare (12%). ICD severity increased over time with ongoing PD treatment, and most patients reported a mild to moderate impact of their ICD on close relationships, family, mental and physical health.ConclusionsThis study identified insufficient communication about ICDs as part of clinical care in PD and a very limited involvement of mental health services. Thus, to improve prevention and treatment, ICDs should be recognized, monitored and treated more systematically in routine clinical care, and collaboration with mental health services should be increased.</p>","PeriodicalId":16660,"journal":{"name":"Journal of Parkinson's disease","volume":" ","pages":"1877718X251323922"},"PeriodicalIF":4.0,"publicationDate":"2025-03-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143649446","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Seeding amplification assay: Limitations and insights for enhanced clinical and research applications.","authors":"Ilham Y Abdi, Sara A Hashish, Omar A El-Agnaf","doi":"10.1177/1877718X251325124","DOIUrl":"https://doi.org/10.1177/1877718X251325124","url":null,"abstract":"<p><p>The accurate diagnosis of synucleinopathies-neurodegenerative diseases marked by misfolded α-synuclein protein aggregates, such as Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy-remains a critical challenge. Conventional clinical criteria, frequently verified only through postmortem examination, results in diagnostic delays that impede timely intervention. Seeding amplification assay (SAA) has emerged as a promising diagnostic tool, offering high sensitivity for detecting α-synuclein aggregates even in early disease stages. While SAA enables early diagnosis by amplifying misfolded α-synuclein in biological samples, several barriers exist, including a lack of assay standardization, technical complexity, and difficulty differentiating among synucleinopathies. Additionally, the current SAA is primarily qualitative, limiting their ability to correlate with disease severity or progression. This review addresses these limitations by examining pre-analytical and analytical factors influencing SAA performance and exploring emerging quantitative approaches. Recent advancements include the integration of SAA with quantitative methodologies, which hold promise for enhanced diagnostic accuracy and clinical applicability. SAA's potential as a diagnostic and monitoring tool is significant and can be further improved by validation in longitudinal studies. The clinical implementation of SAA could revolutionize the early detection and management of synucleinopathies, ultimately improving patient outcomes through earlier diagnosis and tailored therapeutic strategies.</p>","PeriodicalId":16660,"journal":{"name":"Journal of Parkinson's disease","volume":" ","pages":"1877718X251325124"},"PeriodicalIF":4.0,"publicationDate":"2025-03-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143537327","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cerebrospinal ceramides and cognition as a function of striatal asymmetry in early stage of Parkinson's disease.","authors":"Anthony Nuber-Champier, Philippe Voruz, Ioana Constantin, Alexandre Cionca, Julie A Péron","doi":"10.1177/1877718X251319242","DOIUrl":"https://doi.org/10.1177/1877718X251319242","url":null,"abstract":"<p><strong>Background: </strong>Parkinson's disease (PD) is characterized by heterogeneous clinical phenotypes that may be influenced by the asymmetry of striatal denervation. The alpha-Synuclein Origin site and Connectome (SOC) model proposes that different disease onset patterns-\"body first\" versus \"brain first\"-affect symptom development and cognitive decline.</p><p><strong>Objective: </strong>This study aims to explore the relationship between striatal denervation asymmetry, ceramide metabolism, and cognitive performance in early-stage PD.</p><p><strong>Methods: </strong>We analyzed data from 329 patients with PD at baseline, categorized by the type of putamen denervation asymmetry predominance at baseline, along with data from 167 healthy controls. We performed generalized linear mixed models introducing ceramides levels and cognitive performance as discriminating factors. Spearman correlations were used to highlight the relationship between cognition and ceramides.</p><p><strong>Results: </strong>Our findings revealed that patients with asymmetric striatal denervation exhibited higher concentrations of C18:0 ceramides compared to both symmetric patients and healthy controls. Moreover, patients with symmetric denervation demonstrated greater cognitive impairment than those with right or left asymmetry.</p><p><strong>Conclusions: </strong>The study highlights the importance of striatal denervation asymmetry in influencing ceramide metabolism and cognitive function in early-stage PD. These findings suggest that specific ceramide profiles may serve as metabolic markers to distinguish clinical phenotypes, providing insights into disease progression.</p>","PeriodicalId":16660,"journal":{"name":"Journal of Parkinson's disease","volume":" ","pages":"1877718X251319242"},"PeriodicalIF":4.0,"publicationDate":"2025-03-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143537326","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Psilocybin-assisted psychotherapy for Parkinson's disease without depression: A case-report.","authors":"Vanessa Fleury, Emilie Tomkova, Sabina Catalano Chiuvé, Louise Penzenstadler","doi":"10.1177/1877718X241312604","DOIUrl":"10.1177/1877718X241312604","url":null,"abstract":"<p><p>BackgroundPsychedelic assisted psychotherapy (PAP) can improve treatment-resistant depression. Its usefulness in Parkinson's disease (PD) is unknown. PD patients may have problems adjusting to their chronic progressive neurological disease. A change from emotional avoidance to acceptance has been reported following psilocybin administration in patients with treatment-resistant depression.ObjectiveTo report for the first time the effect of psilocybin in a PD patient.MethodsA non-depressed 43-year-old female with a 2-year history of PD presented with difficulty adjusting to PD, anxious ruminations and pessimism. The patient declined an increase in dopaminergic medication or the introduction of an anxiolytic. Therapeutic patient education was not beneficial. The patient received four sessions of high-dose PAP within one year. Neurological and psychiatric assessments were performed before and at one year follow-up using qualitative interviews and quantitative assessment of motor status, dispositional optimism, depression, anxiety, apathy, and well-being.ResultsPAP was well tolerated. It significantly improved the patient's overall pessimistic outlook on her future and decreased her anxious ruminations and worries about potential handicap due to PD. Her general well-being improved, as well as all psychometric scores except for the apathy scale. Motor status remained unchanged. Better acceptance of PD allowed her to accept pharmacological treatment adjustment.ConclusionsPAP could be a safe and useful treatment for PD patients with dispositional pessimism and difficulties accepting their disease by promoting profound decentration from habitual thoughts and emotions, improving mood and PD acceptance. Randomized, controlled studies are needed to confirm this result.</p>","PeriodicalId":16660,"journal":{"name":"Journal of Parkinson's disease","volume":" ","pages":"440-444"},"PeriodicalIF":4.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143457896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A possible pathway to freezing of gait in Parkinson's disease.","authors":"Stewart A Factor, David Weinshenker, J Lucas McKay","doi":"10.1177/1877718X241308487","DOIUrl":"10.1177/1877718X241308487","url":null,"abstract":"<p><p>Freezing of gait (FOG), a common, perplexing gait disorder observed in Parkinson's disease (PD), is a leading cause of injurious falls and contributes significantly to social isolation. Unlike other PD cardinal features, FOG appears to develop independently, and its heterogeneity presents challenges for both definition and measurement. The pathophysiological mechanisms underlying FOG remain poorly understood, limiting the development of effective treatments. Although the roles of specific, targetable biomarkers in FOG development remain unidentified, evidence suggests that it is likely multimodal, potentially involving extranigral transmitter circuits. The diversity of FOG phenotypes may also reflect underlying differences in pathophysiology. In this paper, we first present evidence that FOG may occur independently of dopaminergic influence. We then review an expanding body of research supporting the hypothesis that FOG arises from a dysfunctional pathophysiological feedback loop, involving norepinephrine (NE) depletion, neuroinflammation, and amyloid-β (Aβ) accumulation. This biological disruption occurs concurrently with, but distinct from, the primary dopaminergic pathology of PD. When they occur on the background of dopamine loss, the interactions between NE, Aβ, and inflammation, as observed in Alzheimer's disease models, may similarly play a critical role in the development of FOG in PD and could serve as pathobiological markers. The proposed changes in the pathophysiological loop might even precede its onset, highlighting the need for further investigation. A deeper understanding of the involvement of Aβ, NE, and inflammatory markers in FOG could pave the way for rapid clinical trials to test existing amyloid-clearing therapies and noradrenergic drugs in appropriate patient populations.</p>","PeriodicalId":16660,"journal":{"name":"Journal of Parkinson's disease","volume":" ","pages":"282-290"},"PeriodicalIF":4.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143458447","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cortical α4β2-nicotinic acetylcholine receptors and cognitive decline in Parkinson's disease.","authors":"Kelly A Mills, Hiroto Kuwabara, Yong Du, Gabriela Gomez, Chelsie S Motley, Yana Skorobogatova, Ergi Spiro, Jennifer M Coughlin, Wojciech Lesniak, Jason Brandt, Vidya Kamath, Martin G Pomper, Gwenn S Smith","doi":"10.1177/1877718X241313373","DOIUrl":"10.1177/1877718X241313373","url":null,"abstract":"<p><p>BackgroundAutopsy and <i>in vivo</i> molecular imaging studies suggest altered binding of the α4β2-nicotinic cholinergic receptor (α4β2-nAChR) with cognitive dysfunction in Parkinson's disease (PD).ObjectiveTo determine the relationship between cortical and hippocampal binding of the α4β2-nAChR with [¹⁸F]XTRA PET, a high-affinity radiotracer that enables quantification of α4β2-nAChR in these regions, and cognitive function in individuals with PD.MethodsIndividuals with PD (N = 32) and age-similar, controls without PD or dementia (N = 10) completed a cognitive assessment and one 90-min, [¹⁸F]XTRA PET scan. Metabolite-corrected arterial input function radioactivity time-activity curves were generated to obtain total distribution volume (V_T) across 12 regions of interest (ROIs). [¹⁸F]XTRA binding was compared 1) between controls and people with PD and 2) between controls, persons with PD with normal cognition (PD-NC), and persons with PD with MCI (PD-MCI).Results[¹⁸F]XTRA binding was higher in the occipital cortex of the combined group of PD participants compared to age-similar controls. No regions showed lower binding in PD. V_T with, but not without, partial volume correction was different between controls, PD-NC, and PD-MCI groups, and this was driven by higher binding in PD-MCI compared to controls. Regression of regional V_T on cognitive domain T-scores, adjusting for age, showed that worse performance in visual-spatial memory tasks was associated with higher V_T in the precuneus and the entire parietal cortex.ConclusionsHigher α4β2-nAChR binding in posterior cortical regions is found in PD and associated with worse visual perception and memory, possibly due to lower receptor occupancy by endogenous acetylcholine.</p>","PeriodicalId":16660,"journal":{"name":"Journal of Parkinson's disease","volume":" ","pages":"374-386"},"PeriodicalIF":4.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143458482","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Concordance between imaging and clinical based STN-DBS programming improves motor outcomes of directional stimulation in Parkinson's disease.","authors":"Leonardo Rigon, Francesco Bove, Alessandro Izzo, Nicola Montano, Livia Brusa, Rocco Cerroni, Alessandro De Biase, Lazzaro di Biase, Giorgio Quintino D'Alessandris, Danilo Genovese, Pasquale Maria Pecoraro, Antonella Peppe, Marina Rizzo, Alessandro Stefani, Antonio Suppa, Anna Rita Bentivoglio, Paolo Calabresi, Carla Piano","doi":"10.1177/1877718X241305725","DOIUrl":"10.1177/1877718X241305725","url":null,"abstract":"<p><p>BackgroundAdvances in STN-DBS technology, among which directional stimulation, improved Parkinson's disease (PD) treatment efficacy, while increasing the clinical programming complexity. Lead localization software may aid the stimulation contact selection process.ObjectiveWe aimed to assess the concordance between imaging-suggested (IGP) and conventional-programming (CP) selected stimulation contacts one year after surgery and its impact on motor outcomes.MethodsSixty-four PD patients with bilateral STN-DBS were enrolled. Lead localization was reconstructed with Brainlab^TM software. For each electrode, the vertical contact level and, when applicable, the directionality predicted by the lead reconstruction software to be the most effective were established and compared to the stimulation parameters clinically activated one-year post-surgery. IGP/CP concordance ratio was calculated for both stimulation level and directional contacts. Post-operative modifications of PD motor symptoms severity were compared among groups of concordant and discordant IGP/CP programming.ResultsOne-year post-surgery, IGP/CP concordance was 80% for active stimulation vertical contact level and 51% for directionality. No significant difference in motor outcomes was found between IGP/CP concordant and discordant patients for contact level activation, whereas patients with concordant IGP/CP active directional stimulation (c-Direction) showed superior motor outcomes at one-year follow-up than those discordant (d-Direction) (UPDRS-III stimulation-induced improvement: c-Direction = -25.66 ± 13.74 vs. d-Direction = -12.54 ± 11.86; p = 0.011).ConclusionsVisual reconstruction software correctly predicted the most clinically effective stimulation contact levels in most patients. Imaging therefore facilitates classic STN-DBS clinical programming while assuring similar outcomes. Moreover, better motor outcomes were reached by patients with concordant IGP/CP directional parameters, suggesting that visualization can represent an added value in particular for directional stimulation programming.</p>","PeriodicalId":16660,"journal":{"name":"Journal of Parkinson's disease","volume":" ","pages":"409-420"},"PeriodicalIF":4.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143649443","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}